Clinical trials
Placebo - Control clinical trials
Below are recruiting placebo - control clinical trials, each written for real people, not researchers. We’re tracking 3,902 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05712200RecruitingPhase 3
Abelacimab for atrial fibrillation when blood thinners aren’t suitable
This Phase 3 study tests whether abelacimab can prevent stroke and other blood-clot problems in people with atrial fibrillation (or atrial flutter) who cannot safely take usual mouth blood thinners. It also looks at safety, especially bleeding risk.
Birmingham, AlabamaAges 65 years+ - NCT05723198RecruitingPhase 3
Baricitinib for severe childhood hair loss from alopecia areata
This trial tests whether baricitinib can improve severe alopecia areata (patchy, autoimmune hair loss) in children and teens. It’s meant for people who have had long-lasting, severe hair loss and have tried other treatments without enough benefit.
Birmingham, AlabamaAges 6–17 - NCT05711394RecruitingPhase 3
Atogepant for preventing episodic migraine in children
This study tests whether an oral medicine called atogepant can reduce migraine activity in children ages 6–17 and checks its side effects. It’s meant for kids with episodic migraine (not the more constant types) who may benefit from preventive treatment.
Huntsville, AlabamaAges 6–17 - NCT05735483Enrolling by invitationPhase 3
Long-term lebrikizumab study for moderate to severe eczema
This Phase 3 trial studies whether lebrikizumab is safe and continues to work over the long term for children and teens with moderate-to-severe atopic dermatitis (eczema). It’s meant for people who already finished a related earlier study and can safely continue.
Birmingham, AlabamaAges 6 months–18 years - NCT05716100RecruitingPhase 3
Study drug for focal epilepsy that isn’t controlled on current meds
This trial tests XEN1101 compared with a placebo (inactive pill) in people with focal-onset seizures that haven’t been fully controlled despite trying at least two anti-seizure medicines. If you qualify, you may help researchers see whether the study drug reduces seizure frequency and improves control.
Little Rock, ArkansasAges 18 years+ - NCT05722938RecruitingPhase 3
Testing Trimodulin for severe pneumonia on breathing support
This trial tests an investigational medicine called Trimodulin (BT588) for people with severe pneumonia who need a breathing machine. The goal is to see if it helps them recover faster.
Mobile, AlabamaAges 18 years+ - NCT05726032RecruitingPhase 2
Empagliflozin for fluid buildup from cirrhosis
This Phase 2 study tests empagliflozin to see if it can improve fluid buildup (ascites) in people with cirrhosis. It may help reduce symptoms related to fluid retention, but you must meet specific safety and stability requirements.
New Haven, ConnecticutAges 18 years+ - NCT05715411Recruiting
Light therapy for long sleep-onset insomnia
This trial studies whether timed light exposure can help people who have trouble falling asleep. It aims to improve insomnia symptoms by testing a light-based approach while carefully measuring sleep patterns.
StrasbourgAges 30–60 - NCT05744479RecruitingPhase 4
Metformin to reduce weight gain from antipsychotic medicines
This trial tests whether metformin can help adults with intellectual disability who gained weight from long-term antipsychotic medicines. If you qualify, you may be assigned metformin to improve weight and related health measures.
Toronto, OntarioAges 16–65 - NCT05730283RecruitingPhase 2
Preventing hearing damage from IV amikacin in NTM patients
This Phase 2 study looks at ways to prevent hearing damage (ototoxicity) in people with NTM lung infection who are treated with IV amikacin. If you qualify, the study may help protect your hearing while you receive a treatment that can sometimes affect hearing.
San Francisco, CaliforniaAges 18–80 - NCT05713877RecruitingPhase 2
Melatonin to treat confusion in ICU patients
This Phase 2 trial tests whether melatonin can reduce delirium, a sudden confusion that can happen in the ICU. If you qualify, you may be given melatonin to see if it improves alertness and comfort during an expected longer ICU stay.
Montreal, QuebecAges 18 years+ - NCT05739864RecruitingPhase 1/Phase 2
Test of donor gut bacteria for ulcerative colitis
This early-stage study tests whether a one-time transfer of “donor gut bacteria” can improve ulcerative colitis. It’s designed for people with mild to moderate ulcerative colitis who are stable on maintenance treatment.
Rome, LazioAges 18–75 - NCT05739071Enrolling by invitation
Herbal tea study for bladder cancer urinary tract symptoms
This study tests whether drinking JING SI herbal tea can help with urinary tract symptoms in people with bladder cancer receiving treatment directly into the bladder. You may be able to help researchers understand whether this tea improves day-to-day bladder-related symptoms.
Taipei, TaiwanAges 20–100 - NCT04063540RecruitingPhase 2
Amiloride to prevent migraine aura episodes
This study tests whether amiloride can reduce how often migraine aura happens. It’s a proof-of-concept early study, meaning the main goal is to see if the approach seems to work and is safe for people with frequent aura.
BronAges 18–80 - NCT05194397RecruitingPhase 2
Exercise plus NR supplement to boost fitness after stem-cell transplant
This trial tests whether a supervised exercise program, plus an NR supplement, can improve fitness in young people who have had an allogeneic (donor) stem-cell transplant for certain blood cancers or bone marrow conditions. It’s meant to help with energy and physical ability while monitoring safety.
Duarte, CaliforniaAges 10–30 - NCT04924270RecruitingPhase 2
Capsule stool transfer for newly diagnosed inflammatory bowel or joint disease
This Phase 2 study tests whether taking capsule stool (FMT) is safe and can help people who are newly diagnosed and haven’t started the usual medicines yet. Participants will also start the standard first-line treatment for their condition, and the study will compare safety and outcomes.
OdenseAges 18–75 - NCT05677971RecruitingPhase 3
Tested medicine to treat liver scarring in PiZZ alpha-1 disease
This Phase 3 study tests fazirsiran for safety and whether it can help people with a specific genetic form of alpha-1 antitrypsin–related liver disease that causes liver scarring. You may be eligible if you have the PiZZ genetic type and moderate-to-severe fibrosis, with certain lung and liver conditions ruled out.
Birmingham, AlabamaAges 18–75 - NCT05686642RecruitingPhase 2
Drug LT3001 for sudden stroke symptoms within 24 hours
This Phase 2 study tests LT3001 to improve recovery after an acute ischemic stroke (a stroke caused by blocked blood flow). It is designed for people who can be treated within 24 hours of symptom onset and who meet specific safety and health requirements.
Beijing, Beijing MunicipalityAges 18–80 - NCT05701969RecruitingEarly Phase 1
Melatonin for sleep during night shifts in residents
This early study tests whether melatonin can improve sleep patterns for doctors-in-training during overnight “night float” shifts. It may help you feel more rested and adjust to night work.
Charlottesville, VirginiaAges 18 years+ - NCT05703672RecruitingPhase 3
Switching smokers to e-cigarettes who do not want to quit
This study tests whether switching from regular cigarettes to e-cigarettes helps smokers who are not interested in quitting. You would also be offered varenicline and regular check-ins to compare outcomes over time.
Kansas City, MissouriAges 21 years+ - NCT05684692RecruitingPhase 2
Pain-relief study for adults with schwannomatosis
This Phase 2 study tests whether an antibody medicine (either siltuximab or erenumab) can reduce moderate-to-severe pain in adults with schwannomatosis. It compares the medicine to a placebo and looks for improved pain control and tolerability.
Boston, MassachusettsAges 18 years+ - NCT05681299RecruitingPhase 4
Testing growth hormone and liraglutide effects on hunger hormones
This study tests how growth hormone (GH) and liraglutide affect a hunger-related hormone system called AgRP. It compares effects in healthy people (lean or overweight) and in people with isolated GH deficiency, aiming to understand how these treatments change appetite and metabolism.
New York, New YorkAges 18–45 - NCT05702398RecruitingEarly Phase 1
Vitamin A and niacinamide for high-risk skin cancer
This early trial tests whether adding vitamin A and niacinamide (a form of vitamin B3) can help people with a history of certain skin cancers reduce new disease. It is designed for adults with specific prior skin cancer or skin lesion treatment patterns.
Providence, Rhode IslandAges 18 years+ - NCT05681572RecruitingPhase 3
Sedation before surgery to help kids feel better after anesthesia
This study tests whether giving a calming medicine before general anesthesia improves how children feel and experience anesthesia afterward. The goal is to see which pre-surgery approach works best and is comfortable for kids.
Montpellier, MontpellierAges 7–18
Hear when a new Placebo - Control trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for placebo - control?
- Yes. Clin2 currently lists 3,902 recruiting placebo - control studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a placebo - control trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a placebo - control trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.